<DOC>
	<DOCNO>NCT00652795</DOCNO>
	<brief_summary>To compare rate extent absorption doxycycline tablet ( Par ) versus doxycycline capsule ( Monodox ) ( Oclassen ) .</brief_summary>
	<brief_title>Bioequivalence Study Doxycycline Tablets Monodox Capsules Under Fasting Conditions</brief_title>
	<detailed_description>To compare rate extent absorption doxycycline 150 mg tablet ( test ) versus Monodox 50 mg capsule ( reference ) administer 1 x 50 mg tablet 3 x 50 mg capsule fast condition .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Male nonchildbearing potential female , smoker nonsmoker 18 year age old Nonchildbearing potential female subject define postmenopausal state : absence menses 12 month prior drug administration hysterectomy bilateral oophorectomy , tubal ligation least 6 month prior drug administration Capable consent Clinically significant illness within 4 week administration study medication Clinically significant surgery within 4 week prior administration study medication Any clinically significant abnormality find medical screen Any reason , opinion medical subinvestigator , would prevent subject participate study Abnormal laboratory test judge clinically significant Positive testing hepatitis B , hepatitis C HIV screen ECG abnormality vital sign abnormality screen BMI great equal 30.0 kg/m2 History significant alcohol abuse within six month screen visit indication regular use fourteen unit alcohol per week History drug abuse use illegal drug : soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , PCP , crack ) within 1 year prior screen visit positive urine drug screen screen History allergic reaction heparin , doxycycline , relate drug Use drug know induce inhibit hepatic drug metabolism within 30 day prior administration study medication Use investigational drug participation investigational study , within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology , unresolved gastrointestinal symptom , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease Use prescription medication within 14 day prior administration study medication overthecounter product within 7 day prior administration study medication , except topical product without systemic absorption Difficulty swallow study medication Smoking 25 cigarette per day Any food allergy , intolerance , restriction special diet , opinion Medical SubInvestigator , could contraindicate subject 's participation study A depot injection implant drug within 3 month prior administration study medication Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication ( 50 mL 300 mL whole blood within 30 day , 301 mL 500 mL whole blood within 45 day , 500 mL whole blood within 56 day prior drug administration ) History presence clinically significant gastrooesophageal reflux , stomach ulcer , indigestion History presence clinically significant severe renal hepatic dysfunction History presence clinically significant myasthenia gravis Breastfeeding subject Positive urine pregnancy screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>doxycycline monohydrate</keyword>
	<keyword>fast</keyword>
</DOC>